The FDA’s recent inclusion of certain GLP-1 receptor agonists on a so-called “Green List” is often portrayed as a regulatory milestone aimed at ensuring safer access to these increasingly popular medications. However, beneath the surface, this policy move may ironically serve to legitimize and even entrench a burgeoning gray market around GLP-1 drugs, with profound […] Op-Ed: How The FDA’s Green List For GLP-1 Drugs Fuels The Gray Market Problem ...read more read less